These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 28541801)

  • 1. Enemies or weapons in hands: investigational anti-diabetic drug glibenclamide and cancer risk.
    Gao R; Yang T; Xu W
    Expert Opin Investig Drugs; 2017 Jul; 26(7):853-864. PubMed ID: 28541801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glibenclamide Mimics Metabolic Effects of Metformin in H9c2 Cells.
    Salani B; Ravera S; Fabbi P; Garibaldi S; Passalacqua M; Brunelli C; Maggi D; Cordera R; Ameri P
    Cell Physiol Biochem; 2017; 43(3):879-890. PubMed ID: 28954268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
    Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATP-sensitive potassium channels contribute to the time-dependent alteration in the pentylenetetrazole-induced seizure threshold in diabetic mice.
    Ghasemi M; Shafaroodi H; Karimollah AR; Gholipour T; Nezami BG; Ebrahimi F; Dehpour AR
    Seizure; 2010 Jan; 19(1):53-8. PubMed ID: 20004596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulphonylureas and cancer: a case-control study.
    Monami M; Lamanna C; Balzi D; Marchionni N; Mannucci E
    Acta Diabetol; 2009 Dec; 46(4):279-84. PubMed ID: 19082520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
    Zinman B; Haffner SM; Herman WH; Holman RR; Lachin JM; Kravitz BG; Paul G; Jones NP; Aftring RP; Viberti G; Kahn SE;
    J Clin Endocrinol Metab; 2010 Jan; 95(1):134-42. PubMed ID: 19875477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
    Maffioli P; Fogari E; D'Angelo A; Perrone T; Derosa G
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1113-22. PubMed ID: 23524525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
    Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
    Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metformin, an antidiabetic molecule with anti-cancer properties].
    Beck E; Scheen AJ
    Rev Med Liege; 2013 Sep; 68(9):444-9. PubMed ID: 24180199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
    Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
    J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin.
    Barnett AH; Dreyer M; Lange P; Serdarevic-Pehar M
    Diabetes Care; 2006 Aug; 29(8):1818-25. PubMed ID: 16873786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Protective Role of Glibenclamide in Inflammation-Associated Injury.
    Zhang G; Lin X; Zhang S; Xiu H; Pan C; Cui W
    Mediators Inflamm; 2017; 2017():3578702. PubMed ID: 28740332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation.
    Farmer RE; Ford D; Forbes HJ; Chaturvedi N; Kaplan R; Smeeth L; Bhaskaran K
    Int J Epidemiol; 2017 Apr; 46(2):728-744. PubMed ID: 28031313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Medication of the month. Glucovance in type 2 diabetes, a fixed combination of metformin-glibenclamide for the treatment of a bipolar metabolic disease].
    Scheen AJ
    Rev Med Liege; 2003 Jun; 58(6):448-52. PubMed ID: 12945247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
    Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
    Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin: response to Barnett et al.
    Kanna B; Abreu-Pacheco H
    Diabetes Care; 2007 Feb; 30(2):445-6; author reply 446. PubMed ID: 17259531
    [No Abstract]   [Full Text] [Related]  

  • 18. [New clinical data with metformin therapy in patients with diabetes mellitus].
    Jermendy G
    Orv Hetil; 2010 Dec; 151(49):2025-30. PubMed ID: 21106483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.
    Goo AK; Carson DS; Bjelajac A
    J Fam Pract; 1996 Jun; 42(6):612-8. PubMed ID: 8656173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects.
    Prescrire Int; 2014 Nov; 23(154):269-72. PubMed ID: 25954799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.